» Articles » PMID: 16107155

Defunctionalized Lobeline Analogues: Structure-activity of Novel Ligands for the Vesicular Monoamine Transporter

Overview
Journal J Med Chem
Specialty Chemistry
Date 2005 Aug 19
PMID 16107155
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

(-)-Lobeline (2R,6S,10S), an antagonist at nicotinic acetylcholine receptors (nAChRs), inhibits the neurochemical and behavioral effects of methamphetamine and inhibits dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) function. VMAT2 is a target for the development of treatments for methamphetamine abuse. Structural modification of lobeline affords the defunctionalized analogues meso-transdiene (MTD) and lobelane, which have high potency and selectivity for VMAT2. To establish the structure-activity relationships within this novel class of VMAT2 ligands, specific stereochemical forms of MTD, lobelane, and other structurally related analogues have been synthesized. These compounds have been evaluated for inhibition of [(3)H]nicotine ([(3)H]NIC) binding (alpha4beta2 nAChR), [(3)H]methyllycaconitine ([(3)H]MLA) binding (alpha7 nAChR), and [(3)H]dihydrotetrabenazine ([(3)H]DTBZ) binding (VMAT2). Generally, all of these analogues had lower affinities at alpha4beta2 and alpha7 nAChRs compared to lobeline, thereby increasing selectivity for VMAT2. The following structural modifications resulted in only modest changes in affinity for VMAT2, affording analogues that were less potent than the lead compound, lobelane: (1) altering the stereochemistry at the C-2 and C-6 positions of the piperidino ring, (2) varying unsaturation in the piperidino C-2 and C-6 substituents, (3) introducing unsaturation into the piperidine ring, (4) ring-opening or eliminating the piperidine ring, and (5) removing the piperidino N-methyl group. Furthermore, incorporating a quaternary ammonium group into defunctionalized lobeline molecules in the cis-series resulted in significant loss of affinity for VMAT2, whereas only a modest change in affinity was obtained in the trans-series. The most potent (K(i) = 630 nM) and VMAT2-selective compound evaluated was the N-methyl-2,6-cis-bis(naphthaleneethyl)piperidine analogue (1-NAP-lobelane), in which the phenyl groups of lobelane were replaced with 1-naphthyl moieties. Thus, initial structure-activity relationship studies reveal that the most promising structural changes to the lobeline molecule that lead to enhancement of VMAT2 affinity and selectivity are defunctionalization, affording lobelane and MTD, and replacement of the phenyl rings of lobelane with other aromatic moieties that have a pi-extended structure.

Citing Articles

From -Lobeline to -Lobeline: Study on the Pharmacodynamics and Isomerization Factors.

Xu H, Yang L, Tang M, Ye A, Tu B, Jiang Z Molecules. 2022; 27(19).

PMID: 36234790 PMC: 9573392. DOI: 10.3390/molecules27196253.


Beyond Alkaloids: Novel Bioactive Natural Products From Species.

Zheng Q, Wang Y, Zhang S Front Pharmacol. 2021; 12:638210.

PMID: 33762957 PMC: 7982472. DOI: 10.3389/fphar.2021.638210.


GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine.

Lee N, Zheng G, Leggas M, Janganati V, Nickell J, Crooks P J Pharmacol Exp Ther. 2019; 371(2):526-543.

PMID: 31413138 PMC: 6863457. DOI: 10.1124/jpet.119.258699.


Mannich-type Reactions of Cyclic Nitrones: Effective Methods for the Enantioselective Synthesis of Piperidine-containing Alkaloids.

Lisnyak V, Lynch-Colameta T, Snyder S Angew Chem Int Ed Engl. 2018; 57(46):15162-15166.

PMID: 30276949 PMC: 7199385. DOI: 10.1002/anie.201809799.


New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders.

Lee N, Zheng G, Crooks P, Bardo M, Dwoskin L AAPS J. 2018; 20(2):29.

PMID: 29427069 PMC: 7047575. DOI: 10.1208/s12248-018-0192-y.


References
1.
Brown J, Hanson G, Fleckenstein A . Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem. 2000; 74(5):2221-3. DOI: 10.1046/j.1471-4159.2000.0742221.x. View

2.
Miller D, Crooks P, Dwoskin L . Lobeline inhibits nicotine-evoked [(3)H]dopamine overflow from rat striatal slices and nicotine-evoked (86)Rb(+) efflux from thalamic synaptosomes. Neuropharmacology. 2000; 39(13):2654-62. DOI: 10.1016/s0028-3908(00)00140-4. View

3.
Brown J, Hanson G, Fleckenstein A . Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther. 2001; 296(3):762-7. View

4.
Miller D, Crooks P, Teng L, Witkin J, Munzar P, Goldberg S . Lobeline inhibits the neurochemical and behavioral effects of amphetamine. J Pharmacol Exp Ther. 2001; 296(3):1023-34. View

5.
Harrod S, Dwoskin L, Crooks P, Klebaur J, Bardo M . Lobeline attenuates d-methamphetamine self-administration in rats. J Pharmacol Exp Ther. 2001; 298(1):172-9. View